You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
McKinsey
Harvard Business School
Medtronic

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

TRIFERIC Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Triferic patents expire, and when can generic versions of Triferic launch?

Triferic is a drug marketed by Rockwell Medical Inc and is included in three NDAs. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

US ANDA Litigation and Generic Entry Outlook for Triferic

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 8, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for TRIFERIC
Drug Prices for TRIFERIC

See drug prices for TRIFERIC

Generic Entry Opportunity Date for TRIFERIC
Generic Entry Dates for TRIFERIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SOLUTION;INTRAVENOUS
Generic Entry Dates for TRIFERIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIFERIC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rockwell Medical Technologies, Inc.Phase 3
Rockwell Medical Technologies, Inc.Phase 2
Rockwell Medical Technologies, Inc.Phase 1/Phase 2

See all TRIFERIC clinical trials

Pharmacology for TRIFERIC

US Patents and Regulatory Information for TRIFERIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate FOR SOLUTION;INTRAVENOUS 208551-001 Apr 25, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-002 Sep 4, 2015 DISCN Yes No   Start Trial   Start Trial   Start Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate FOR SOLUTION;INTRAVENOUS 208551-001 Apr 25, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRIFERIC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015   Start Trial   Start Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
Colorcon
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.